Directors appointed by the Enterprise Chamber have cleared the path for an extraordinary general meeting to finalize the proposed merger between OCI Global and Orascom Construction PLC. NNS Holding, the primary shareholder behind the initiative known as Rembrandt II, confirmed its unwavering support for the deal following the announcement.
Oceanwood Capital Management has moved to disentangle itself from the ongoing legal dispute involving OCI Global, notifying the Dutch Shareholders Association (VEB) on July 1, 2026, that it is formally withdrawing the power of attorney previously granted to the organization regarding proceedings in the Enterprise Chamber.
The Enterprise Chamber has cleared the path for an extraordinary general meeting of shareholders to vote on the proposed merger between OCI Global and Orascom Construction PLC, known as Rembrandt II. In the wake of this development, NNS Holding, the largest shareholder in OCI, has formally reaffirmed its commitment to the deal.
Three parallel vertical-lift bridges in Newark, New Jersey, are undergoing a major structural transformation as Amtrak moves to stabilize its critical Northeast Corridor infrastructure. Skanska has been tapped for the $87 million rehabilitation project, aiming to convert the aging movable spans into a permanent, fixed configuration by late 2028.
Proximus has tapped Ekinops for a decade-long partnership to overhaul Belgium’s telecommunications backbone. The initiative, dubbed NEURON, will see the French provider deploy high-speed optical infrastructure across more than 600 sites, transitioning the nation’s network to 800 Gbit/s capacity with future-ready support for 1.6T speeds.
Investors who purchased BitGo Holdings, Inc. securities between January 22 and May 13, 2026, face an August 7 deadline to petition the court to serve as lead plaintiff. The litigation, initiated by the Rosen Law Firm, alleges that the company's IPO registration documents contained material misstatements and omissions.
Investors who purchased ADMA Biologics, Inc. securities between August 9, 2024, and March 25, 2026, face an August 10, 2026, deadline to serve as lead plaintiff in a class action lawsuit. The litigation targets alleged misrepresentations regarding the company’s internal financial controls and revenue reporting practices.
Fosun International has been recognized with five major accolades at the 16th Asian Excellence Awards, including top honors for its leadership. The prestigious ceremony, hosted by Corporate Governance Asia, celebrated the group’s commitment to sustainable business practices, environmental stewardship, and innovative global strategy throughout the 2025 fiscal year.
Takeda has entered a strategic partnership with Insilico Medicine to overhaul its drug discovery pipeline using generative artificial intelligence. The deal, which grants the Japanese pharmaceutical giant exclusive worldwide rights to resulting therapies, could see Insilico collect up to $600 million in milestone payments and tiered royalties.
A new 400MWh battery energy storage portfolio is set to bolster grid stability across Eastern Europe, following a strategic contract signing between Jinko ESS and Taliva Energy. The deal, finalized at Intersolar Europe, pairs Jinko’s high-performance hardware with Taliva’s regional development expertise to accelerate the continent’s renewable energy integration.
Investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, face an August 10, 2026, deadline to seek lead plaintiff status in an ongoing securities class action. The lawsuit alleges the company misled shareholders regarding the clinical prospects of its lead drug candidate, ERAS-0015.
Investors who purchased First Solar, Inc. securities between February 26, 2025, and February 24, 2026, face an August 24, 2026, deadline to move the court to serve as lead plaintiff in a pending class action lawsuit filed by the Rosen Law Firm.
With an investment exceeding A$1 billion in Northern Star Resources, Elliott Investment Management has signaled its intent to force a strategic shift at the mining company. The firm issued a public statement following Northern Star’s recent announcements, demanding immediate board enhancement and a comprehensive review of the company's long-term corporate direction.
Suzhou-based Ribo and U.S.-based Madrigal Pharmaceuticals have hit their first major development milestone, officially nominating a lead candidate drug for metabolic dysfunction-associated steatohepatitis. The partnership, formed just months ago, now moves into IND-enabling studies to prepare for upcoming clinical trials targeting the liver disease.
Over 180 delegates from 70 regulatory and law enforcement bodies gathered in Hungary this week for the International Association of Anti-Corruption Authorities’ first European regional conference. The summit marks a strategic shift toward localized regional clusters to combat increasingly complex, cross-border financial crimes.
A strategic partnership between Suzhou Ribo Life Science and Madrigal Pharmaceuticals has reached its first major milestone, successfully nominating a lead candidate drug for metabolic dysfunction-associated steatohepatitis. The companies are now transitioning into IND-enabling studies to prepare for upcoming clinical trials.
Montréal-based security firm GardaWorld has priced a $200 million offering of senior notes due 2032 while simultaneously securing commitments for a $300 million expansion of its existing term loan. The move, expected to close by July 6, underscores strong investor appetite for the company’s ongoing global expansion strategy.
A new class action lawsuit filed in Santa Clara County Superior Court alleges that Nvidia Corporation systematically denied employees mandatory meal and rest periods. The complaint, brought by Blumenthal Nordrehaug Bhowmik De Blouw LLP, further accuses the tech giant of failing to reimburse staff for mandatory work-related mobile phone usage.
Shanghai-based Abbisko Therapeutics has secured a strategic partnership with AstraZeneca to launch a Phase I/II clinical trial testing the combination of a novel oral PD-L1 inhibitor, lumipodlin, with the established lung cancer drug Tagrisso. The study targets patients with EGFR-mutated, PD-L1 positive non-small cell lung cancer.
Montréal-based security giant GardaWorld is expanding its capital reserves, pricing a US$200 million addition to its 2032 senior notes while simultaneously securing commitments for a US$300 million expansion of its existing term loan facility to bolster its acquisition strategy and general corporate operations.
Austin-based Summit Hotel Properties plans to disclose its financial performance for the second quarter of 2026 on August 5, following the close of market trading. The real estate investment trust, which currently manages a portfolio of 94 lodging assets across 24 states, will detail its results during a subsequent conference call.
Nona Biosciences and Lonza have launched a strategic collaboration to engineer single-domain antibody technology capable of crossing the blood-brain barrier. The partnership aims to facilitate the delivery of therapeutic agents directly into the central nervous system, addressing a significant hurdle in the treatment of complex neurological disorders.
A 19.12% drop in Omeros Corporation stock has triggered a formal investigation by the Pomerantz Law Firm. The inquiry focuses on potential securities fraud following the European Medicines Agency’s rejection of the company’s marketing authorization application for narsoplimab, a drug intended to treat transplant-associated thrombotic microangiopathy.
A 40.71 percent single-day stock collapse following a debt-offering announcement has triggered a formal investigation by Pomerantz LLP. The law firm is currently scrutinizing Hertz Global Holdings for potential securities fraud and unlawful business practices, targeting the company's recent move to raise 300 million dollars in senior secured notes.
A scathing report from Umibōzu Research has triggered a securities investigation into EquipmentShare.com Inc. after allegations of systemic self-dealing surfaced. The inquiry, led by Pomerantz LLP, centers on whether the company and its leadership misled shareholders regarding undisclosed financial transactions involving its founders, Jabbok and Willy Schlacks.
The Ensign Group faces fresh legal scrutiny as Pomerantz LLP launches an investigation into potential securities fraud. This move follows a series of scathing reports from short-sellers Hunterbrook and Muddy Waters, which triggered significant stock declines and raised serious questions regarding the company’s patient care standards and billing practices.
Shares of Onsemi plummeted 23.66% on June 26, erasing $28.09 from the company’s stock price just one day after announcing a $7 billion all-stock takeover of Synaptics. The sharp market reaction has prompted New York-based Pomerantz LLP to launch an investigation into potential securities fraud and executive misconduct.
A 17.2% single-day stock drop has triggered a formal investigation into Hyliion Holdings Corp. by the Pomerantz Law Firm. The inquiry examines whether the company misled shareholders regarding a high-profile, non-binding deal that critics claim lacks the commercial substance required to justify the firm’s $400 million revenue pipeline.
Investors of Larimar Therapeutics are under scrutiny as Pomerantz LLP examines the company for potential securities fraud. The investigation follows a series of clinical trial disclosures regarding the drug nomlabofusp, which triggered sharp declines in the company's stock price after reports of severe allergic reactions in trial participants.
A sharp 8.02% drop in Copart’s stock price prompted an immediate investigation by Pomerantz LLP into potential securities fraud. The inquiry follows the announcement that CEO Jeff Liaw will resign from his executive position and board seat effective July 31, leaving shareholders to grapple with the sudden leadership transition.
